55 3 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | PART TWO Searching conference proceedings of ASCO, ESMO, and MASCC did not provide additional eligible studies. Characteristics eligible studies Our search provided 9 studies which met the selection criteria [18-26]. Mean sample size was 320 patients. Mean number of patients receiving non-AC MEC was 230. All but three studies assesses patients with various tumor types. A Most studies assessed antiemetics in patients receiving a broad range of chemotherapy regimens, including HEC, AC and MEC regimens; three studies assessed non-AC MEC only. Most studies were doubleblinded, including one phase II trial. Three had a crossover study design. Two were noninferiority trials. Palonosetron was assessed in three studies, including one evaluating a dexamethasone-sparing regimen. NK1 receptor antagonists were assessed in three studies, including one evaluating casopitant. Figure 1. Flow chart of included studies Abbreviations: MEC, moderately emetogenic chemotherapy; non-AC, not containing anthracyclines and cyclophosphamide Although casopitant was discontinued for further development, we included data from this RCT because they provide evidence to clarify the usage of NK1 receptor antagonists for non-AC MEC. Other antiemetics assessed were NEPA, olanzapine and megestrol acetate, each in one study. Complete response (CR, defined as “no vomiting”, and/or “no use of rescue antiemetics”) in the acute, delayed, and overall phases was the primary efficacy endpoint in the majority of the studies included. Study details are summarized in Table 1.
RkJQdWJsaXNoZXIy MjY0ODMw